PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Stroke0 citations

Abstract TP305: A Novel Adjuvant Strategy for Futile Reperfusion after Endovascular Therapy: Remote Administration of Hypothermia (RAH) from Peripheral Orgain for Neuroprotection in CNS

View Full Paper
XGXiaokun GengHDhonglian duanZCZhe Cheng

Key Points

  • Evaluate the safety, feasibility, and preliminary efficacy of Remote Administration of Hypothermia (RAH) in neuroprotection after mechanical thrombectomy for acute ischemic stroke.
  • Prospective randomized controlled trial with 40 acute ischemic stroke patients
  • Randomization into RAH and control groups following successful mechanical thrombectomy
  • RAH applied via ice packs over the splenic region for 6 hours post-recanalization
  • No severe adverse events or frostbite were reported, confirming safety
  • RAH group showed a trend toward increased spleen volume, indicating reduced splenic contraction
  • Interleukin-5 levels increased significantly in the RAH group after 5–7 days
  • Favorable trends in 90-day functional independence and reduced infarct volume were noted, though not statistically significant

Abstract

Introduction: While mechanical thrombectomy (MT) is effective for acute ischemic stroke (AIS), many patients fail to achieve meaningful recovery due to ischemia-reperfusion injury and inflammation. The spleen plays a key role in post-stroke immune responses. Our preclinical study showed that Remote Administration of Hypothermia (RAH)—noninvasive cooling over the splenic region—reduces infarct size and inflammation without tissue damage. This study evaluated the safety, feasibility, and preliminary efficacy of RAH as a neuroprotective strategy post-MT. Methods: In this prospective randomized controlled trial (ChiCTR2300077052), 40 AIS patients were randomized 1:1 to RAH or control groups following successful MT. RAH was applied via ice packs over the left abdomen and back for 6 hours post-recanalization. Primary adverse events included cold intolerance and abdominal pain. Secondary outcomes included intracranial hemorrhage (ICH), mortality, modified Rankin Scale (mRS), infarct volume, complications, splenic volume, and peripheral inflammatory markers. Results: All patients completed follow-up. No frostbite or severe adverse events were observed, confirming safety. There were no significant differences in ICH, mortality, or general complications. The RAH group showed a trend toward increased spleen volume (+4.05 vs. -8.16 cm3; p=0.227), suggesting inhibition of AIS-induced splenic contraction. Interleukin-5 was significantly elevated in the RAH group at 5–7 days (1.77 vs. 1.26 pg/mL; p<0.001). Although baseline NIHSS was higher in the RAH group (13.15+/-6.92 vs. 8.95+/-4.61; p=0.030), they showed favorable trends in 90-day functional independence (mRS 0–2: 75.0% vs. 60.0%) and reduced infarct volume (30.9 vs. 37.1 mL), though not statistically significant. Conclusion: RAH post-MT is safe and feasible in AIS patients. It may mitigate post-stroke splenic contraction and inflammation, with favorable clinical trends. Larger trials are needed to confirm its therapeutic potential.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Geng et al. (2026) studied this question.

synapsesocial.com/papers/6980fbf6c1c9540dea80dc97https://doi.org/10.1161/str.57.suppl_1.tp305
Ask AI
Helpful
Bookmark
Share
View Full Paper